Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Bristol-Myers Squibb Co    BMY

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Bristol-Myers Gets SEC Subpoena In Foreign Bribery Probe

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/26/2012 | 07:01pm CEST
   By Peter Loftus 
   Of  
 

Drug maker Bristol-Myers Squibb Co. (>> Bristol Myers Squibb Co.) said it has received a subpoena from the U.S. Securities and Exchange Commission as part of an investigation into bribery overseas.

Bristol-Myers said the subpoena received in March seeks information related to sales and marketing practices in "various countries."

The New York-based company said in a quarterly report filed Thursday with the SEC that it was cooperating with the government. A spokeswoman declined comment beyond the information in Thursday's SEC filing.

Bristol-Myers, which sells the anti-clotting drug Plavix, previously disclosed that the SEC was investigating the activities of the company's units in Germany, concerning potential violations of the U.S. Foreign Corrupt Practices Act, or FCPA.

U.S. authorities in recent years have stepped up enforcement of the FCPA, which bars U.S. companies from bribing foreign officials to obtain or retain business. Multinational drug and medical-device makers based in the U.S. have been among the targets of enforcement.

Last year, Johnson & Johnson (>> Johnson & Johnson) agreed to pay nearly $80 million to resolve allegations that it paid bribes to doctors in three European countries, as well as kickbacks to Iraq to illegally obtain business under former leader Saddam Hussein.

Other drug makers--including Pfizer Inc. (>> Pfizer Inc.), Merck & Co. (>> Merck & Co., Inc.) and Eli Lilly & Co. (>> Eli Lilly & Co.)--also have been the subjects of federal inquiries regarding the FCPA.

-By Peter Loftus, Dow Jones Newswires; +1-215-982-5581; [email protected]

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on BRISTOL-MYERS SQUIBB CO
05/22 BRISTOL-MYERS SQUIBB CO : Blog Coverage: Bristol-Myers Squibs Received EMA Valid..
05/19 BRISTOL MYERS SQUIBB : European Medicines Agency Validates Application for Brist..
05/18 BRISTOL MYERS SQUIBB : Studies from P.J. Mease et al in the Area of Psoriatic Ar..
05/18 BRISTOL MYERS SQUIBB : Trademark Application for "COBLIXRA" Filed
05/18 BRISTOL MYERS SQUIBB : and Calithera Biosciences Expand Collaboration Evaluating..
05/18 BRISTOL MYERS SQUIBB : Investigators at Bristol-Myers Squibb Describe Findings i..
05/18 BRISTOL MYERS SQUIBB : Trademark Application for "BRIVTAGA" Filed by Bristol-Mye..
05/18 BRISTOL MYERS SQUIBB : An Application for the Trademark "CLATAZEV" Has Been File..
05/18 BRISTOL MYERS SQUIBB : Trademark Application for "HESVOCA" Filed
05/18 BRISTOL MYERS SQUIBB : Researchers Submit Patent Application, "Method of Treatin..
More news
Sector news : Pharmaceuticals - NEC
08:35aDJASTRAZENECA : Says Bydureon Trial Meets Safety Objectives; No Significant CV Red..
05/22 Cross-border M&A between U.S. and European firms at 10 year high
05/22DJASTRAZENECA : in Pact with Recordati for Heart-Drug Seloken in Europe
05/19 European shares claw back gains after worst week in six months
05/19 FTSE climbs for fourth straight week, shrugging off Trump slump
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
05/22 Bristol-Myers Squibb (BMY) Management Presents at UBS Global Healthcare Confe..
05/22 My 83 Stock Portfolio Requirements And Listing Of Do Not Sell, Core And Specu..
05/19 Asco Preview - Breast Cancer And I-O Combos Grab The Early Headlines
05/19 EMA to review Bristol-Myers' marketing application for pediatric use of Spryc..
05/18 ESPERION THERAPEUTICS : Up, Up, And Away?
Advertisement
Financials ($)
Sales 2017 20 267 M
EBIT 2017 5 463 M
Net income 2017 4 622 M
Finance 2017 202 M
Yield 2017 2,92%
P/E ratio 2017 19,28
P/E ratio 2018 17,64
EV / Sales 2017 4,39x
EV / Sales 2018 4,24x
Capitalization 89 126 M
More Financials
Chart BRISTOL-MYERS SQUIBB CO
Duration : Period :
Bristol-Myers Squibb Co Technical Analysis Chart | BMY | US1101221083 | 4-Traders
Full-screen chart
Technical analysis trends BRISTOL-MYERS SQU...
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 57,2 $
Spread / Average Target 5,7%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Giovanni Caforio Chairman & Chief Executive Officer
Charles A. Bancroft CFO, EVP & Head-Global Business Operations
Paul von Autenried Chief Information Officer & Senior Vice President
Thomas James Lynch Chief Scientific Officer & Executive VP
Laurie H. Glimcher Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
BRISTOL-MYERS SQUIBB C..-7.43%89 126
JOHNSON & JOHNSON10.23%342 817
ROCHE HOLDING LTD.14.79%237 610
NOVARTIS AG6.28%213 719
PFIZER INC.-1.11%191 279
MERCK & CO., INC.8.78%175 160
More Results